Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Chondrosarcoma is defined as a malignant cartilaginous matrix-producing mesenchymal neoplasm arising from bone and soft tissue. It usually affects middle-aged to elderly adults. The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement. The packet classifies its prevalence as uncommon, with an estimate of 1 to 9 in 100,000. Recognized subtypes listed include bone chondrosarcoma, mesenchymal chondrosarcoma, localized chondrosarcoma, and myxoid chondrosarcoma.
According to the condition description, most chondrosarcomas arise de novo, while some may develop in a preexisting benign cartilaginous lesion. The packet lists a multifactorial inheritance pattern. Gene-level information with supporting validity evidence is not certified in this packet, so no specific genetic cause is described here.
Diagnostic methods and criteria are not certified in this packet.
Treatment coverage is not certified in this packet, and no FDA-approved therapies are listed. Orphan drug designations are recorded for chondrosarcoma for ivosidenib and for a tetravalent recombinant humanized IgG1 agonist antibody targeting the TRAIL death receptor 5. An orphan designation is a regulatory status that does not by itself indicate approval or established benefit.
38 trials found
Prognosis is not certified in this packet.
The packet records clinical trial entries relevant to this condition. These include a phase 3 study of ivosidenib in locally advanced or metastatic conventional chondrosarcoma (NCT06127407, Servier Bio-Innovation, recruiting), a study of clear cell chondrosarcoma in Italy (NCT07360964, Istituto Ortopedico Rizzoli, active, not recruiting), and a phase 2 study in IDH2-mutated sinonasal and skull base tumors (NCT06176989, National Cancer Institute, recruiting). Several listed studies enroll multiple sarcoma or tumor types. Active clinical trials for this condition are listed on ClinicalTrials.gov.
Data assembled from 8 of 12 sources · Last updated Nov 17, 2026, 11:47 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about chondrosarcoma
AI-curated news mentioning chondrosarcoma
Updated Oct 6, 2026
A case report details a patient with recurrent dedifferentiated clival chondrosarcoma occurring 32 years post-initial treatment. This highlights the long-term monitoring needs for patients with this rare tumor type.